by Sean Yao | Sep 14, 2026 | Uncategorized
The designation covers Bright Path’s end-to-end U.S. production of two hospital medicines in chronic shortage, the first proof that essential medicines can be made in America, in most cases at prices that beat China and India MESA, Ariz., Sept. 14, 2026...
by Sean Yao | Aug 30, 2026 | Uncategorized
Bright Path is Transforming America’s Access to Essential Medicines.. Bright Path will be honored with an AZBio Fast Lane Award on Oct. 7, 2026 at the Phoenix Convention Center at the 23 annual AZBio Awards. For years, the U.S. healthcare system has suffered from...
by Sean Yao | Aug 28, 2024 | News
Agreement Awarded by DARPA in partnership with the Administration for Strategic Preparedness and Response’s (ASPR) Center of Industrial Base Management and Supply Chain (IBMSC) Kannapolis, NC / College Station, Tx August 28, 2024 – Bright Path Laboratories, Inc., a...
by Sean Yao | Feb 29, 2024 | News
On Rare Disease Day 2024, Bright Path Laboratories shared an amazing step in our commitment to rare diseases. Bright Path successfully completed the development of Amlexanox as a potential treatment for WOREE Syndrome, a devastating rare disease that affects children...
by Sean Yao | Dec 13, 2023 | News
KANNAPOLIS, N.C., Dec. 13, 2023 /PRNewswire/ — Bright Path Laboratories, a US-based advanced drug development and manufacturing company is proud to announce their contribution to solving drug shortages for the domestic development and manufacturing of two...
